- Home
- RSLS
as 07-26-2024 4:00pm EST
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN CLEMENTE |
| Market Cap: | 4.1M | IPO Year: | 2007 |
| Target Price: | N/A | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.14 - $1.51 | Next Earning Date: | 08-05-2024 |
| Revenue: | $8,335,000 | Revenue Growth: | -24.82% |
| Revenue Growth (this year): | 17.47% | Revenue Growth (next year): | 20.00% |
Stock Insider Trading Activity of ReShape Lifesciences Inc. (RSLS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| STANKOVICH THOMAS | RSLS | Chief Financial Officer | Aug 4 '23 | Sell | $1.43 | 108 | $154.44 | 23,276 | SEC Form 4 |
| STANKOVICH THOMAS | RSLS | Chief Financial Officer | Aug 4 '23 | Sell | $1.42 | 39 | $55.38 | 23,237 | SEC Form 4 |
| STANKOVICH THOMAS | RSLS | Chief Financial Officer | Aug 4 '23 | Sell | $0.89 | 118 | $105.02 | 23,119 | SEC Form 4 |
| STANKOVICH THOMAS | RSLS | Chief Financial Officer | Aug 4 '23 | Sell | $0.93 | 39 | $36.27 | 23,080 | SEC Form 4 |
| STANKOVICH THOMAS | RSLS | Chief Financial Officer | Aug 4 '23 | Sell | $0.27 | 131 | $35.37 | 22,949 | SEC Form 4 |
Latest ReShape Lifesciences Inc. News
RSLS Breaking Stock News: Dive into RSLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
GlobeNewswire
18 days ago
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Business Wire
2 months ago
Net Asset Value(s)
GlobeNewswire
2 months ago
Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%
Business Wire
2 months ago
MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence
GlobeNewswire
2 months ago
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
PR Newswire
2 months ago
Dstny honored with 'Employee Wellbeing Award'
Newsfile
2 months ago
RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon
Compare RSLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RSLS ReShape Lifesciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.